T1	Participants 668 713	matched sibling or unrelated donor transplant
T2	Participants 741 802	prolonged sirolimus administration (â‰¥ 1 year post-transplant)
T3	Participants 804 983	Median follow-up time for surviving patients at time of this analysis was 41 months (range 27-60) for sirolimus/tacrolimus and 49 months (range 29-63) for methotrexate/tacrolimus.
T4	Participants 226 271	allogeneic hematopoietic cell transplantation
